MEDIMAPS GROUP has raised $20 Million to Expand and Commercialize its AI Product Portfolio

MEDIMAPS GROUP, a global medical technology firm specializing in image processing software for bone health assessment, announced today that it has raised $20 million in an institutional asset round led by Zürcher Kantonalbank’s Swisscanto Invest, with participation from Verve Ventures, Swisscom Ventures, and Swiss Entrepreneurs Fund.

The money collected will be utilized to grow its product line by developing and launching proprietary artificial intelligence (AI) apps for bone health evaluation in the United States, Europe, Asia, and Latin America.An osteoporotic fracture happens every three seconds. This is partly due to the fact that 75 percent of high-risk individuals are not detected or tested in a timely way. Because BMD can only evaluate the quantity of bone, not quality of bone, around 40% of patients who have a BMD evaluation are incompletely diagnosed.

TBS iNsight from MEDIMAPS Group enables deep tech bone texture analysis connected to bone microarchitecture to analyze bone quality, allowing doctors to detect patients sooner and quantify their fracture risk, improving patient management and lowering healthcare costs. It has been demonstrated that 30% of osteopenic individuals are categorized as having tuberculosis. Because their system uses already captured pictures, it does not expose the patient to extra radiation, and it integrates easily into the process.

MEDIMAPS‘ unique technology is based on a multi-layer deep learning algorithm. This approach may be used on a variety of image resolutions and modalities, resulting in solutions ranging from opportunistic X-ray screening to patient risk profiling and pre-surgical evaluation.